Table of contents

  • Executive summary

  • Portfolio

    • Antifungal Cresemba® (isavuconazole)

    • Antibiotic Zevtera® (ceftobiprole)

    • Oncology

      • Derazantinib

      • Lisavanbulin

      • BAL0891

  • Financials & Outlook

  • Appendix

Focused on Growth and Innovation

Confidential/proprietary information of Basilea Pharmaceutica International Ltd. - not for distribution

Experienced leadership team

Focused on Growth and Innovation

Confidential/proprietary information of Basilea Pharmaceutica International Ltd. - not for distribution

At a glance

  • Well funded, commercial-stage biopharmaceutical company with significantly growing cash flows from commercialized products

  • Focused in the areas of anti-infectives and oncology

  • Potential for sustainable growth and value creation based on commercialized brands and an innovative pipeline

  • Experienced people with the proven expertise to take compounds from research to market

  • Two revenue generating hospital anti-infective brands, Cresemba® and Zevtera® and three oncology drug candidates

  • Recognized ability to establish and manage partnerships in both the development and commercial phase, providing access to international markets

  • Listed on SIX Swiss Stock Exchange, SIX: BSLN

  • Based in life sciences hub, Basel, Switzerland

Focused on Growth and Innovation

Confidential/proprietary information of Basilea Pharmaceutica International Ltd. - not for distribution

This is an excerpt of the original content. To continue reading it, access the original document here.

Attachments

  • Original Link
  • Original Document
  • Permalink

Disclaimer

Basilea Pharmaceutica AG published this content on 30 March 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 30 March 2022 13:52:05 UTC.